AU2010306698B2 - Treating neurotoxicity associated with combinations of 5 - FU or its prodrugs and DPD inhibitors - Google Patents

Treating neurotoxicity associated with combinations of 5 - FU or its prodrugs and DPD inhibitors Download PDF

Info

Publication number
AU2010306698B2
AU2010306698B2 AU2010306698A AU2010306698A AU2010306698B2 AU 2010306698 B2 AU2010306698 B2 AU 2010306698B2 AU 2010306698 A AU2010306698 A AU 2010306698A AU 2010306698 A AU2010306698 A AU 2010306698A AU 2010306698 B2 AU2010306698 B2 AU 2010306698B2
Authority
AU
Australia
Prior art keywords
prodrug
administered
dpd
eniluracil
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010306698A
Other languages
English (en)
Other versions
AU2010306698A1 (en
Inventor
Thomas Spector
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fennec Pharmaceuticals Inc
Original Assignee
Adherex Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adherex Technologies Inc filed Critical Adherex Technologies Inc
Publication of AU2010306698A1 publication Critical patent/AU2010306698A1/en
Application granted granted Critical
Publication of AU2010306698B2 publication Critical patent/AU2010306698B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2010306698A 2009-10-14 2010-10-14 Treating neurotoxicity associated with combinations of 5 - FU or its prodrugs and DPD inhibitors Active AU2010306698B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25144909P 2009-10-14 2009-10-14
US61/251,449 2009-10-14
PCT/US2010/052734 WO2011047195A1 (en) 2009-10-14 2010-10-14 Treating neurotoxicity associated with combinations of 5 - fu or its prodrugs and dpd inhibitors

Publications (2)

Publication Number Publication Date
AU2010306698A1 AU2010306698A1 (en) 2012-05-17
AU2010306698B2 true AU2010306698B2 (en) 2016-05-26

Family

ID=43466528

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010306698A Active AU2010306698B2 (en) 2009-10-14 2010-10-14 Treating neurotoxicity associated with combinations of 5 - FU or its prodrugs and DPD inhibitors

Country Status (14)

Country Link
US (1) US8658618B2 (enExample)
EP (1) EP2488182B1 (enExample)
JP (2) JP2013508293A (enExample)
KR (1) KR20120127709A (enExample)
CN (1) CN102811721A (enExample)
AU (1) AU2010306698B2 (enExample)
BR (1) BR112012008951A2 (enExample)
CA (1) CA2777546C (enExample)
CO (1) CO6541596A2 (enExample)
EA (1) EA201270551A1 (enExample)
ES (1) ES2644237T3 (enExample)
IL (1) IL219179A0 (enExample)
MX (1) MX2012004383A (enExample)
WO (1) WO2011047195A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089004A1 (en) * 2012-12-04 2014-06-12 Adherex Technologies, Inc. Methods for treating 5-fluorouracil prodrug non-responsive cancer patients
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用
JP2025538758A (ja) * 2022-12-06 2025-11-28 エリオン・オンコロジー・インコーポレイテッド がんを治療するためのエニルウラシル及びカペシタビンの併用
TW202517270A (zh) * 2023-07-13 2025-05-01 美商普羅塞沙製藥公司 癌症治療個人化方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817664A (en) * 1990-09-26 1998-10-06 Glaxo Wellcome Inc. Uracil reductase inactivators
WO2006060697A1 (en) * 2004-12-03 2006-06-08 Adherex Technologies, Inc. Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5687599A (en) 1979-12-19 1981-07-16 Yamasa Shoyu Co Ltd E 55 22halogenovinyl arabinofuranosyluracil and its preparation
GB8629892D0 (en) 1986-12-15 1987-01-28 Wellcome Found Antiviral compounds
US5157114A (en) 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
WO1992001452A1 (en) * 1990-07-19 1992-02-06 The Wellcome Foundation Limited Enzyme inactivators
US5476855A (en) 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817664A (en) * 1990-09-26 1998-10-06 Glaxo Wellcome Inc. Uracil reductase inactivators
WO2006060697A1 (en) * 2004-12-03 2006-06-08 Adherex Technologies, Inc. Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAO S, et al., Cancer Research, (1994) Vol 54, pp 1507-1510. *
KEITH B, et al., Clinical Cancer Research, (2002) Vol 8, pp 1045-1050. *
SPECTOR T, et al., Cancer Research, (1995) Vol 55, pp 1239-1241. *

Also Published As

Publication number Publication date
KR20120127709A (ko) 2012-11-23
JP2013508293A (ja) 2013-03-07
EP2488182B1 (en) 2017-07-19
JP2016014051A (ja) 2016-01-28
IL219179A0 (en) 2012-06-28
US20110130359A1 (en) 2011-06-02
US8658618B2 (en) 2014-02-25
CA2777546C (en) 2019-11-05
CA2777546A1 (en) 2011-04-21
EP2488182A1 (en) 2012-08-22
EA201270551A1 (ru) 2012-12-28
AU2010306698A1 (en) 2012-05-17
CO6541596A2 (es) 2012-10-16
CN102811721A (zh) 2012-12-05
MX2012004383A (es) 2012-08-23
BR112012008951A2 (pt) 2019-09-24
WO2011047195A1 (en) 2011-04-21
ES2644237T3 (es) 2017-11-28

Similar Documents

Publication Publication Date Title
US20130184232A1 (en) Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
JP5576591B2 (ja) α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
Hong et al. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS‐102 in patients with solid tumors
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
CN114727996A (zh) 用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷
AU2010306698B2 (en) Treating neurotoxicity associated with combinations of 5 - FU or its prodrugs and DPD inhibitors
JP6990934B2 (ja) 異所性脂肪蓄積治療用ａ３アデノシン受容体リガンド
KR20240108406A (ko) 2'-데옥시시티딘 유사체를 포함하는 조성물 및 겸상 적혈구 질환, 지중해빈혈, 및 암의 치료를 위한 그의 용도
JP2007508299A (ja) 全身性抗癌治療の間の器官保護のための方法、組成物、およびキット
AU2012200856B2 (en) Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
US20080255168A1 (en) Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
WO2014089004A1 (en) Methods for treating 5-fluorouracil prodrug non-responsive cancer patients
HK1110531A (en) Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
WO2022014025A1 (ja) 血液がんの新規治療法及び新規治療剤
Fujita et al. Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)